Farxiga OK’d for Kids; Semaglutide Price Hearing; Maintaining GLP-1 Weight Loss

The FDA approved dapagliflozin (Farxiga) for glycemic control in children ages 10 years and older with type 2 diabetes, based on results from the phase III T2NOW trial, AstraZeneca announced.

Novo Nordisk’s CEO agreed to testify before a Senate committee in a hearing on the price of semaglutide (Ozempic, Wegovy). (Reuters)

Childhood obesity rates in Chile didn’t change much after banning Tony the Tiger and other cartoon characters on sugary foods. (STAT)

“It is crucial to diagnose and treat diabetic patients who have concomitant thyroid disease as early as possible to prevent further complications and optimize outcomes,” said authors of a Frontiers in Endocrinology case report.

People who lost at least 40 lbs with the GLP-1 receptor agonists semaglutide and liraglutide (Saxenda) were more likely to maintain or continue their weight loss a year after treatment discontinuation compared with those who lost less weight, data in Epic Research indicated.

Democrats blocked a GOP bill that would take away states’ Medicaid funding if they bar in vitro fertilization (IVF) services, arguing that the bill does not go far enough to protect IVF access. (The Hill)

In pregnant women with type 2 diabetes, continuing metformin and adding insulin in early pregnancy was tied to little to no increased risk for non-live birth compared with switching to insulin monotherapy. (Annals of Internal Medicine)

Intensive glucose control was not associated with reduced mortality risk in critically ill adults, but was linked to an increased risk of severe hypoglycemia. (NEJM Evidence)

Singer Usher — whose child was diagnosed with type 1 diabetes in 2014 — took to Capitol Hill to advocate for more accessible type 1 diabetes screening. (ABC News)

A federal judge ruled that Florida’s new restrictions on gender-affirming treatment for children and adults are unconstitutional. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.